Retirement Systems of Alabama Increases Stock Position in Humana Inc. (NYSE:HUM)

Retirement Systems of Alabama increased its position in Humana Inc. (NYSE:HUM) by 735.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 219,002 shares of the insurance provider’s stock after purchasing an additional 192,801 shares during the quarter. Retirement Systems of Alabama’s holdings in Humana were worth $55,563,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. AMF Tjanstepension AB boosted its stake in Humana by 166.8% during the 3rd quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after acquiring an additional 25,041 shares during the last quarter. Park Avenue Securities LLC boosted its stake in Humana by 17.3% during the 3rd quarter. Park Avenue Securities LLC now owns 4,857 shares of the insurance provider’s stock valued at $1,538,000 after acquiring an additional 718 shares during the last quarter. Czech National Bank boosted its stake in Humana by 6.8% during the 3rd quarter. Czech National Bank now owns 24,527 shares of the insurance provider’s stock valued at $7,769,000 after acquiring an additional 1,564 shares during the last quarter. GAMMA Investing LLC boosted its stake in Humana by 78.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,352 shares of the insurance provider’s stock valued at $428,000 after acquiring an additional 593 shares during the last quarter. Finally, Atwood & Palmer Inc. bought a new position in Humana during the 3rd quarter valued at $29,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.29% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on HUM. KeyCorp began coverage on shares of Humana in a research note on Friday, October 11th. They set a “sector weight” rating on the stock. Truist Financial increased their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. TD Cowen increased their target price on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Finally, Piper Sandler increased their target price on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Humana has a consensus rating of “Hold” and an average price target of $297.68.

Humana Stock Performance

NYSE:HUM opened at $295.68 on Wednesday. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average of $275.13 and a 200-day moving average of $300.37. The firm has a market cap of $35.60 billion, a price-to-earnings ratio of 26.19, a price-to-earnings-growth ratio of 2.21 and a beta of 0.56.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.